FDA con­verts No­var­tis' NSCLC drug to a full ap­proval with con­fir­ma­to­ry da­ta

Al­though No­var­tis dis­con­tin­ued its re­search in­to the use of Tabrec­ta in sol­id tu­mors, the FDA on Thurs­day an­nounced that its ac­cel­er­at­ed ap­proval would be con­vert­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER